skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Role of tipranavir in treatment of patients with multidrug-resistant HIV



Review

(4322) Total Article Views


Authors: Joshua D Courter, Colleen J Teevan, Michael H Li, et al

Published Date September 2010 Volume 2010:6 Pages 431 - 441
DOI: http://dx.doi.org/10.2147/TCRM.S4207

Joshua D Courter1,2, Colleen J Teevan1, Michael H Li1, Jennifer E Girotto1,2, Juan C Salazar1,2,3
1University of Connecticut School of Pharmacy, Storrs, 2Connecticut Children’s Medical Center, Hartford, 3University of Connecticut School of Medicine, Hartford, Connecticut, USA

Abstract: The worldwide emergence of multidrug-resistant human immunodeficiency virus (HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have become available for treatment. It is important to assess how these new ARVs might be most judiciously used, paying close attention to viral susceptibility patterns, pharmacodynamic parameters, and the likelihood that patients will adhere to their therapy. Herein we review published material in Medline, EMBASE, and ISI for each antiretroviral agent/classes currently approved and summarize the available data on their efficacy, safety, and pharmacologic parameters. We focus on the role of tipranavir, a recently approved nonpeptidic PI, for treating HIV-infected children, adolescents, and adults with a history of multidrug-resistant HIV.

Keywords: tipranavir, HIV, multidrug resistance


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: